PMID- 26540343
OWN - NLM
STAT- MEDLINE
DCOM- 20161007
LR  - 20221121
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 6
IP  - 40
DP  - 2015 Dec 15
TI  - LINC00152 promotes proliferation in hepatocellular carcinoma by targeting EpCAM 
      via the mTOR signaling pathway.
PG  - 42813-24
LID - 10.18632/oncotarget.5970 [doi]
AB  - Hepatocellular carcinoma (HCC) is well known as the sixth most common malignant 
      tumor and the third leading cause of cancer-related deaths globally. LINC00152 
      was documented as an important long non-coding RNA (lncRNA) involved in the 
      pathogenesis of gastric cancer; however, the detailed mechanism of action of 
      LINC00152 remains unknown. Here, based on the increased level of LINC00152 in HCC 
      tissues, we found that LINC00152 could promote cell proliferation in vitro and 
      tumor growth in vivo. Furthermore, microarray-based analysis indicated that 
      LINC00152 could activate the mechanistic target of rapamycin(mTOR) pathway by 
      binding to the promoter of EpCAM through a cis-regulation, as confirmed by 
      Gal4-lambdaN/BoxB reporter system. Thus, LINC00152 might be involved in the 
      oncogenesis of HCC by activating the mTOR signaling pathway and might be a novel 
      index for clinical diagnosis in the future.
FAU - Ji, Jie
AU  - Ji J
AD  - Liver Transplantation Center of The First Affiliated Hospital and Collaborative 
      Innovation Center For Cancer Personalized Medicine, Nanjing Medical University, 
      Nanjing, Jiangsu Province, P.R. China.
FAU - Tang, Junwei
AU  - Tang J
AD  - Liver Transplantation Center of The First Affiliated Hospital and Collaborative 
      Innovation Center For Cancer Personalized Medicine, Nanjing Medical University, 
      Nanjing, Jiangsu Province, P.R. China.
FAU - Deng, Lei
AU  - Deng L
AD  - Liver Transplantation Center of The First Affiliated Hospital and Collaborative 
      Innovation Center For Cancer Personalized Medicine, Nanjing Medical University, 
      Nanjing, Jiangsu Province, P.R. China.
FAU - Xie, Yu
AU  - Xie Y
AD  - Liver Transplantation Center of The First Affiliated Hospital and Collaborative 
      Innovation Center For Cancer Personalized Medicine, Nanjing Medical University, 
      Nanjing, Jiangsu Province, P.R. China.
FAU - Jiang, Runqiu
AU  - Jiang R
AD  - Liver Transplantation Center of The First Affiliated Hospital and Collaborative 
      Innovation Center For Cancer Personalized Medicine, Nanjing Medical University, 
      Nanjing, Jiangsu Province, P.R. China.
FAU - Li, Guoqiang
AU  - Li G
AD  - Liver Transplantation Center of The First Affiliated Hospital and Collaborative 
      Innovation Center For Cancer Personalized Medicine, Nanjing Medical University, 
      Nanjing, Jiangsu Province, P.R. China.
FAU - Sun, Beicheng
AU  - Sun B
AD  - Liver Transplantation Center of The First Affiliated Hospital and Collaborative 
      Innovation Center For Cancer Personalized Medicine, Nanjing Medical University, 
      Nanjing, Jiangsu Province, P.R. China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cell Adhesion Molecules)
RN  - 0 (EPCAM protein, human)
RN  - 0 (Epithelial Cell Adhesion Molecule)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (RNA, Small Interfering)
RN  - 0 (long non-coding RNA Linc00152, human)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Aged
MH  - Animals
MH  - Antigens, Neoplasm/genetics/metabolism
MH  - Blotting, Western
MH  - Carcinoma, Hepatocellular/genetics/metabolism/*pathology
MH  - Cell Adhesion Molecules/genetics/metabolism
MH  - *Cell Proliferation/genetics
MH  - Cell Transformation, Neoplastic/genetics
MH  - Chromatin Immunoprecipitation
MH  - Epithelial Cell Adhesion Molecule
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/*physiology
MH  - Gene Knockdown Techniques
MH  - Heterografts
MH  - Humans
MH  - Liver Neoplasms/genetics/metabolism/*pathology
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Nude
MH  - Middle Aged
MH  - Oligonucleotide Array Sequence Analysis
MH  - RNA, Long Noncoding/*genetics
MH  - RNA, Small Interfering
MH  - Real-Time Polymerase Chain Reaction
MH  - Signal Transduction/*physiology
MH  - TOR Serine-Threonine Kinases/genetics/metabolism
PMC - PMC4767473
OTO - NOTNLM
OT  - EpCAM
OT  - HCC
OT  - lncRNA
OT  - mTOR
OT  - prognosis
COIS- CONFLICTS OF INTEREST The authors declare no competing financial interests.
EDAT- 2015/11/06 06:00
MHDA- 2016/10/08 06:00
PMCR- 2015/12/15
CRDT- 2015/11/06 06:00
PHST- 2015/04/27 00:00 [received]
PHST- 2015/10/16 00:00 [accepted]
PHST- 2015/11/06 06:00 [entrez]
PHST- 2015/11/06 06:00 [pubmed]
PHST- 2016/10/08 06:00 [medline]
PHST- 2015/12/15 00:00 [pmc-release]
AID - 5970 [pii]
AID - 10.18632/oncotarget.5970 [doi]
PST - ppublish
SO  - Oncotarget. 2015 Dec 15;6(40):42813-24. doi: 10.18632/oncotarget.5970.